Acarix Ab (ACIXF)

$0.04 +0.01 (26.10%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 400,000
Avg Vol 256,746
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.

Industry: Medical Devices
Sector: Healthcare
Address:
Regus MalmOe, Hyllie Boulevard 34, 5TR, Malmö, Sweden
Pandurotwo
Pandurotwo Jul. 29 at 12:26 PM
$ACIXF Our comment As we have repeatedly emphasised, reimbursement remains a core pillar of the investment case. Monday’s press release, therefore, marks another significant step forward, with a second US payor agreeing to a fixed reimbursement of USD300 for the CADScor System. The first agreement was announced in mid-June 2025 with a regional Third-Party Administrator based in Oklahoma (link to our note). Historically, private payors have tended to align on reimbursement levels and the adoption of fixed reimbursement structures. We therefore believe this development could mark the early stages of a domino effect, with additional private payors likely to follow. The market reacted positively to the press release, with the share now trading around our base case of SEK0.40. We consider this move justified and would not be surprised if the market begins to price in a bull case scenario should positive news flow continue and revenue growth follow.” They keep their estimates…
0 · Reply
Pandurotwo
Pandurotwo Jul. 29 at 7:16 AM
$ACIXF Acarix receives reembursement from the second private payer. https://lnkd.in/dbUG7hUj Qoute:”Acarix CADScor was added at $300 in July to a high-performance provider network to enhance care and cost savings. This Payer provides a Network that services employers and individuals in the Oklahoma, Texas, Ohio, and Louisiana markets which consists of over 500,000 covered lives with 12,000+ Primary Care Physicians, 69.000+ Specialists and 3,000+ Facilities/Ancillaries”. Unqoute.
0 · Reply
Pandurotwo
Pandurotwo Jul. 8 at 2:34 PM
$ACIXF Break through order in the MENA region
0 · Reply
Pandurotwo
Pandurotwo Jul. 7 at 3:31 PM
$ACIXF Global focusing must mean Acarix is satisfied with the way the US market is developing which is good news.
0 · Reply
Pandurotwo
Pandurotwo Jun. 26 at 7:49 AM
$ACIXF Announcement from the CEO:
0 · Reply
Pandurotwo
Pandurotwo Jun. 25 at 9:19 AM
$ACIXF Latest analysis from pharmacoEconomics. Awaiting PM on this as this has great effect on Acarix. Qoute: Results Base case results demonstrated that a CADScor-First strategy was cost saving compared with other noninvasive cardiac tests without a substantial difference in adverse events. Economic results were consistent when coronary artery disease (CAD) prevalence rates were varied from 2 to 30% and across a variety of sensitivity analyses. The overall cost savings were estimated to be $7.3–15.3 million USD per 10,000 patients with low-risk chest pain. Unqoute. https://link.springer.com/article/10.1007/s41669-025-00590-2
0 · Reply
Pandurotwo
Pandurotwo Jun. 16 at 5:17 PM
$ACIXF BINGO !! Acarix: First fixed US reimbursement for CADscor secured Research Note Monday June 16 Redeye endorses today’s news that Acarix has secured a fixed reimbursement of USD300 for the CADScor System. This represents a key milestone in the company’s US commercialisation efforts. Furthermore, we anticipate a potential snowball effect could follow, with additional private payors likely also to provide fixed reimbursement in the near future.
0 · Reply
Pandurotwo
Pandurotwo Apr. 19 at 9:59 AM
$ACIXF Info now that Q1 is to be revealed on Mai 12.. Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind. Full year 2024 results: kr0.072 loss per share (improved from kr0.16 loss in FY 2023). Revenue: kr6.20m (flat on FY 2023). Net loss: kr66.2m (loss narrowed 15% from FY 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. I trust EPS Q1 is close to zero if not positive. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
0 · Reply
Pandurotwo
Pandurotwo Mar. 31 at 9:47 AM
It seems no one is in here thus I'll stop writing myself... $ACIXF
0 · Reply
Pandurotwo
Pandurotwo Mar. 17 at 6:48 PM
$ACIXF CEO buy's stock on 11th and 12th March. 1.2 mill. shares in total.
0 · Reply
Latest News on ACIXF
No data available.
Pandurotwo
Pandurotwo Jul. 29 at 12:26 PM
$ACIXF Our comment As we have repeatedly emphasised, reimbursement remains a core pillar of the investment case. Monday’s press release, therefore, marks another significant step forward, with a second US payor agreeing to a fixed reimbursement of USD300 for the CADScor System. The first agreement was announced in mid-June 2025 with a regional Third-Party Administrator based in Oklahoma (link to our note). Historically, private payors have tended to align on reimbursement levels and the adoption of fixed reimbursement structures. We therefore believe this development could mark the early stages of a domino effect, with additional private payors likely to follow. The market reacted positively to the press release, with the share now trading around our base case of SEK0.40. We consider this move justified and would not be surprised if the market begins to price in a bull case scenario should positive news flow continue and revenue growth follow.” They keep their estimates…
0 · Reply
Pandurotwo
Pandurotwo Jul. 29 at 7:16 AM
$ACIXF Acarix receives reembursement from the second private payer. https://lnkd.in/dbUG7hUj Qoute:”Acarix CADScor was added at $300 in July to a high-performance provider network to enhance care and cost savings. This Payer provides a Network that services employers and individuals in the Oklahoma, Texas, Ohio, and Louisiana markets which consists of over 500,000 covered lives with 12,000+ Primary Care Physicians, 69.000+ Specialists and 3,000+ Facilities/Ancillaries”. Unqoute.
0 · Reply
Pandurotwo
Pandurotwo Jul. 8 at 2:34 PM
$ACIXF Break through order in the MENA region
0 · Reply
Pandurotwo
Pandurotwo Jul. 7 at 3:31 PM
$ACIXF Global focusing must mean Acarix is satisfied with the way the US market is developing which is good news.
0 · Reply
Pandurotwo
Pandurotwo Jun. 26 at 7:49 AM
$ACIXF Announcement from the CEO:
0 · Reply
Pandurotwo
Pandurotwo Jun. 25 at 9:19 AM
$ACIXF Latest analysis from pharmacoEconomics. Awaiting PM on this as this has great effect on Acarix. Qoute: Results Base case results demonstrated that a CADScor-First strategy was cost saving compared with other noninvasive cardiac tests without a substantial difference in adverse events. Economic results were consistent when coronary artery disease (CAD) prevalence rates were varied from 2 to 30% and across a variety of sensitivity analyses. The overall cost savings were estimated to be $7.3–15.3 million USD per 10,000 patients with low-risk chest pain. Unqoute. https://link.springer.com/article/10.1007/s41669-025-00590-2
0 · Reply
Pandurotwo
Pandurotwo Jun. 16 at 5:17 PM
$ACIXF BINGO !! Acarix: First fixed US reimbursement for CADscor secured Research Note Monday June 16 Redeye endorses today’s news that Acarix has secured a fixed reimbursement of USD300 for the CADScor System. This represents a key milestone in the company’s US commercialisation efforts. Furthermore, we anticipate a potential snowball effect could follow, with additional private payors likely also to provide fixed reimbursement in the near future.
0 · Reply
Pandurotwo
Pandurotwo Apr. 19 at 9:59 AM
$ACIXF Info now that Q1 is to be revealed on Mai 12.. Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind. Full year 2024 results: kr0.072 loss per share (improved from kr0.16 loss in FY 2023). Revenue: kr6.20m (flat on FY 2023). Net loss: kr66.2m (loss narrowed 15% from FY 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. I trust EPS Q1 is close to zero if not positive. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
0 · Reply
Pandurotwo
Pandurotwo Mar. 31 at 9:47 AM
It seems no one is in here thus I'll stop writing myself... $ACIXF
0 · Reply
Pandurotwo
Pandurotwo Mar. 17 at 6:48 PM
$ACIXF CEO buy's stock on 11th and 12th March. 1.2 mill. shares in total.
0 · Reply
Pandurotwo
Pandurotwo Mar. 14 at 9:20 AM
$ACIXF PM ! Acarix Named 2025 Digital Innovation Winner by Global Cardiovascular Awards.
0 · Reply
Pandurotwo
Pandurotwo Mar. 13 at 10:54 PM
$ACIXF From "X" Marlou and Christian Representing Acarix in London on the night of the awards, 13th March 2025.
0 · Reply
Pandurotwo
Pandurotwo Mar. 13 at 10:48 PM
$ACIXF Digital Innovation Award. CADScor System. https://globalcardiovascularawards.com/globalcardiovascularawards2025/en/page/2025-shortlist
0 · Reply
Pandurotwo
Pandurotwo Feb. 5 at 12:30 PM
$ACIXF - OKLAHOMA CITY — Acarix, a pioneer in the development of groundbreaking acoustic-based cardiac diagnostic solutions, is proud to announce a new strategic partnership with Geo-Med, LLC, a renowned Service-Disabled Veteran-Owned Small Business that specializes in medical and surgical products for the Department of Veterans Affairs and Department of Defense. This partnership signifies Acarix’s dedication towards enhancing the availability of advanced medical technologies to America’s veterans. Geo-Med’s deep expertise in providing high-quality medical products to the VA and Department of Defense, along with their insight into VA procurement, will be instrumental in ensuring that the CADScor System by Acarix reaches the veterans who need it most. Aamir Mahmood, President and CEO of Acarix, remarked, “This is a monumental win for Acarix as we unite with Geo-Med’s considerable capabilities and reach. Together, we are set to drive forward….
0 · Reply
Pandurotwo
Pandurotwo Jan. 27 at 12:59 PM
$ACIXF By aamir:Exciting advancements are happening in the world of AI and CAD detection. A recent grant from the National Institutes of Health is funding the use of AI in CT scans to enhance CAD diagnostics. At Acarix we see opportunities to pair our #CADScor System’s acoustic-based technology with tools like AI-enhanced CT imaging. By combining these innovations, we can deliver a more comprehensive approach to diagnosing CAD, improving accuracy and prioritizing patient care. These developments highlight the potential for groundbreaking collaborations, transforming how we approach cardiovascular health and setting a new standard for the industry. https://thedaily.case.edu/researchers-harness-ai-to-predict-cardiovascular-risk-from-ct-scans/?fbclid=IwY2xjawIEYURleHRuA2FlbQIxMQABHdsO8Jsaa4T0elDqIc2puLOhClSfT7m7QbgMX3PHPFNUg1jgYvETAbXzaA_aem_IobgyZrTfwyuX4YZ15ZkxA
0 · Reply
Pandurotwo
Pandurotwo Dec. 16 at 1:04 PM
$ACIXF The Shorters has left Acarix ie we're under the limit which require listing. Source: Swedish Financial Institute.
0 · Reply
Frelseren
Frelseren Nov. 4 at 8:12 AM
$ACIXF 🚀🚀🚀🚀
0 · Reply
Pandurotwo
Pandurotwo Oct. 26 at 4:06 AM
$ACIXF While we wait... A small picture of some of the latest, from "our" Danish production. This facilities is in Copenhagen Denmark, same as one of the Acarix offices. The company has increased the number of employees from January 2024: 15 employees, to the present date: 19. (Yes, noted. -It has been observed that they produce for others as well, but 25% more employees probably say one or the other). CADScor V3.
0 · Reply
Pandurotwo
Pandurotwo Oct. 24 at 5:36 AM
$ACIXF 🔔 One Month Away! 🍎 Join us at the OTC Market Center in #NYC on November 20th for our Swedish Investor Conference, featuring some of Sweden’s most exciting growth companies from sectors including biotech, medtech, gaming, and artificial intelligence. We’re thrilled to have Erik Ullenhag, Consul General of #Sweden in New York, providing welcome remarks on Swedish-American relations. 👑 🤝 🎟 Get your ticket here: https://lnkd.in/eStKVcKJ Schedule Wednesday, November 20 · 9am - 6pm EST Free reservation: $0.00 https://www.eventbrite.com/.../swedish-investor-day... Event Sponsor: NanoCap Group Thomas Jansson
0 · Reply
Pandurotwo
Pandurotwo Oct. 21 at 11:51 AM
$ACIXF Following the Redeye broadcast, ceo, Aamir visited the production i Copenhagen. (Can they up production to meet an increased demand in 2025 x10? Just a thought..).
2 · Reply
Pandurotwo
Pandurotwo Oct. 20 at 12:56 PM
$ACIXF The CADscor device spread like rings in the water: https://www.instagram.com/themodeldoc/reel/C5bJK4HAX1x/ https://www.instagram.com/reel/DBFcwrPpKqA/?igsh=YnQza2trdTI2aGNq
0 · Reply
Pandurotwo
Pandurotwo Oct. 18 at 7:42 PM
$ACIXF In case you missed the live broadcast on Redeye. Here is a link to the event which doesn't require Log-In.: https://www.redeye.se/video/event-presentation/1043991/acarix-ceo-aamir-mahmood-presents-at-redeye-cardiovascular-metabolic-diseases-event-2024-17-october You'll probably notice one particular thing and wonder wtf..
0 · Reply